The 8th Guangdong-Hong Kong-Macao Greater Bay Area Biotech Innovation Top 50 Selection has officially commenced. Technoderma Medicines, Inc . (hereinafter referred to as "Technoderma Medicines") was awarded a "Pioneer Enterprise" on th
January 6,2025,Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment in patients with Atopic Dermati
On December 9, 2024, clinical-stage biopharmaceutical company Technoderma Medicines Inc. (hereinafter referred to as "Technoderma") officially announced that its topical ointment TDM-180935, a JAK1/Tyk2 dual-target inhibitor developed for atopic
Technoderma Medicines Advances TDM-180935 Atopic Dermatitis Clinical Program with Phase 2 Trial
CHENGDU – February 5, 2024Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed its Phase 2a clinical trial (NCT05802173) of TDM-105795 topical solution for Androgeneti
Technoderma Medicines, Inc.is a clinical stage biopharmaceutical company.
The company's current core research and development programs include innovative drugs for the treatment of androgenic alopecia, eczema/atopic dermatitis, psoriasis and lupus. TDM-105795, the world's leading small-molecule drug candidate for the treatment of androgenic alopecia, has now completed 2a clinical trials. TDM-180935, a novel JAK1/TYK2 inhibitor for eczema/atopic dermatitis, has also completed a Phase 1 clinical trial in December 2023 with favorable safety results, and Phase 2 a POC clinical trials are underway in the United States.
